Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cinclus Pharma Holding ABOSTO:CINPHA -2.61%6 Market Cap is kr555.66 Mil as of Jul. 25, 2026. GuruFocus rates OSTO:CINPHA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 66.96% on this metric.
Cinclus Pharma Holding AB's quarterly market cap
increased
from Sep. 2025 (kr813.48 Mil) to Dec. 2025 (kr896.32 Mil) but then
declined
from Dec. 2025 (kr896.32 Mil) to Mar. 2026 (kr785.56 Mil).
Cinclus Pharma Holding AB's annual market cap
increased
from Dec. 2023 (kr0.00 Mil) to Dec. 2024 (kr994.98 Mil) but then
declined
from Dec. 2024 (kr994.98 Mil) to Dec. 2025 (kr896.32 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cinclus Pharma Holding AB's Enterprise Value for Today is kr132.74 Mil.
Cinclus Pharma Holding AB (OSTO:CINPHA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cinclus Pharma Holding AB Market Cap Related Terms
Cinclus Pharma Holding AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cinclus Pharma Holding AB (OSTO:CINPHA) has a Market Cap of kr555.66 Mil as of Jul. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cinclus Pharma Holding AB and its competitors. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #685 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 67%.
Is Cinclus Pharma Holding AB's Market Cap too high?
Cinclus Pharma Holding AB's current Market Cap is kr555.66 Mil. Based on the distribution chart, Cinclus Pharma Holding AB ranks #685 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #685 out of 1023 companies for Market Cap. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median Market Cap is 213.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.63, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current Market Cap is kr555.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a current Market Cap of kr555.66 Mil. The current Market Cap is kr555.66 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cinclus Pharma Holding AB (OSTO:CINPHA), the current Market Cap is kr555.66 Mil as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score
Get the complete analysis for OSTO:CINPHA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CINPHA has been successfully added to your 
